Trial of long-acting malaria injectable to launch in Rwanda
The trial of the MMV371 compound will assess efficacy and absorption in Rwanda, led by Rinda Ubuzima.

A trial of the first long-acting injectable for malaria prevention is set to launch in Rwanda this week. The trial, led by Rwandan health research organisation Rinda Ubuzima, will assess the efficacy of the injectable and how participants absorb and process the compound.
The compound, known as MMV371, was developed by the not-for-profit Medicines for Malaria Venture in partnership with UK drug company Quotient. Earlier trials in the UK showed the long-acting injectable provides protection for around three months.
Dr Cristina Donini, executive vice-president of research and development at MMV, said the compound would be complementary to existing tools rather than replacing them. She said that if a tool could cover a broader population with a longer regimen, it would help eliminate the disease.
Researchers hope that if the trial shows the injectable is effective, it could be used for adolescents, adults, older children, and pregnant women. While there are currently two vaccines against malaria, the RTS,S and R21, they are for very young children only and require a schedule of four doses.
The trial comes as malaria continues to impact sub-Saharan Africa, where there were 282 million cases and 610,000 deaths in 2024. Climate change is pushing malaria-carrying mosquitoes into new areas, and the parasite is developing resistance against standard treatments.
Dr Donini and her colleagues are working on a second generation long-acting injectable that they hope would provide year-long coverage. Full costs have not yet been worked out, but Dr Donini said affordability is an important factor in assessing suitability.
Key facts
- A trial for the MMV371 long-acting malaria injectable begins in Rwanda this week.
- The trial is being led by the Rwandan health research organisation Rinda Ubuzima.
- In 2024, there were 282 million malaria cases and 610,000 deaths, mostly in sub-Saharan Africa.
Three perspectives
Neutral
The trial in Rwanda will assess the efficacy and absorption of the MMV371 long-acting injectable.
Positive
Lottie Renwick of Malaria No More UK said the injectable could be a valuable addition to the toolbox by providing sustained protection from a single shot.
Negative
Full costs for the injectable have not yet been worked out.
Your week in news, every Wednesday
The biggest stories of the week for your edition, in your inbox every Wednesday morning, your time. Free, and you can unsubscribe at any time.